AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry

The US FDA has granted market approval for the first pharmacogenetic test using a DNA microarray, the AmpliChip CYP450, which genotypes cytochrome P450 (CYP)2D6 and CYP2C19. The test uses software to predict phenotypes and tests for 27 CYP2D6 alleles, including the deletions and duplications, and three CYP2C19 alleles. Other DNA microarray platforms are being developed for CYP testing, but none have been completely developed or approved by the FDA to date. The differences between an implementation of pharmacogenetic tests centered on the individual and implementation using a public health approach are discussed. In this review, the major obstacles to the wide implementation of pharmacogenetic testing in the clinical environment are summarized.

[1]  Liang-Shang Gan,et al.  Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[2]  A. Grizzle,et al.  Drug-related morbidity and mortality: updating the cost-of-illness model. , 2001, Journal of the American Pharmaceutical Association.

[3]  J Licinio,et al.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.

[4]  M. Wong,et al.  Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. , 2005, BioTechniques.

[5]  R. Kim,et al.  Molecular basis of ethnic differences in drug disposition and response. , 2001, Annual review of pharmacology and toxicology.

[6]  W. Koch,et al.  Clinical applications of microarray-based diagnostic tests. , 2005, BioTechniques.

[7]  P. Danzon,et al.  The economics of gene therapy and of pharmacogenetics. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  W. Koch.  Technology platforms for pharmacogenomic diagnostic assays , 2004, Nature Reviews Drug Discovery.

[9]  L. D. Bradford,et al.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002, Pharmacogenomics.

[10]  W. Koch,et al.  Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. , 2003, Clinical chemistry.

[11]  P. Wedlund.  The CYP2C19 Enzyme Polymorphism , 2000, Pharmacology.

[12]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[13]  J. Leon,et al.  Pharmacogenomic testing: the cost factor , 2001, The Pharmacogenomics Journal.

[14]  A. Gaedigk,et al.  Identification of CYP2D6 impaired functional alleles in Mexican Americans , 2005, European Journal of Clinical Pharmacology.

[15]  G. Ruaño.  Quo vadis personalized medicine? , 2004, Personalized medicine.

[16]  A. Gaedigk,et al.  Unique CYP2D6 activity distribution and genotype‐phenotype discordance in black Americans , 2002, Clinical pharmacology and therapeutics.

[17]  M. Ingelman-Sundberg,et al.  The African‐specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity , 2002, Clinical pharmacology and therapeutics.

[18]  Allen D. Roses,et al.  Pharmacogenetics and drug development: the path to safer and more effective drugs , 2004, Nature Reviews Genetics.

[19]  Trisha Greenhalgh,et al.  How to read a paper: Papers that report diagnostic or screening tests , 1997, BMJ.

[20]  Jürgen Brockmöller,et al.  Clinical Consequences of Cytochrome P450 2C9 Polymorphisms , 2005, Clinical pharmacology and therapeutics.

[21]  A. Gaedigk,et al.  CYP2D6*36 GENE ARRANGEMENTS WITHIN THE CYP2D6 LOCUS: ASSOCIATION OF CYP2D6*36 WITH POOR METABOLIZER STATUS , 2006, Drug Metabolism and Disposition.

[22]  A. Molven,et al.  Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? , 2001, Pharmacogenetics.

[23]  W. Koch,et al.  The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. , 2005, The Journal of clinical psychiatry.

[24]  L. Emens.  Trastuzumab: Targeted Therapy for the Management of HER-2/neu-Overexpressing Metastatic Breast Cancer , 2005, American journal of therapeutics.

[25]  A. Alderborn,et al.  Determination of CYP2D6 gene copy number by pyrosequencing. , 2005, Clinical chemistry.

[26]  M. Baiget,et al.  Clinical Utility of Thiopurine S-Methyltransferase Genotyping , 2004, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[27]  R. Weinshilboum,et al.  Pharmacogenomics: Bench to bedside. , 2005, Discovery medicine.

[28]  A. Windemuth,et al.  High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital: implications for  personalized drug safety. , 2006, Personalized medicine.